Entero Therapeutics, Inc. (NASDAQ:GRDX) Sees Significant Increase in Short Interest

Entero Therapeutics, Inc. (NASDAQ:GRDX) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 104,553 shares, a growth of 91.8% from the September 15th total of 54,523 shares. Currently, 1.5% of the company’s stock are sold short. Based on an average trading volume of 74,913 shares, the days-to-cover ratio is presently 1.4 days.

Entero Therapeutics Price Performance

Shares of GRDX traded down $0.30 during mid-day trading on Wednesday, reaching $4.25. The company had a trading volume of 62,258 shares, compared to its average volume of 115,623. Entero Therapeutics has a twelve month low of $1.87 and a twelve month high of $6.93. The company’s 50-day moving average is $3.58 and its 200-day moving average is $3.68. The company has a market capitalization of $30.30 million, a P/E ratio of -2.24 and a beta of 1.69.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 29th.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for gastrointestinal disorders. The company’s work is centered on treatments intended to address unmet needs in conditions involving inflammation, immune responses and intestinal health.

Its lead development program is latiglutenase, an oral enzyme therapy designed to break down immunogenic gluten fragments in the digestive tract. The program is being developed for celiac disease, an autoimmune disorder triggered by gluten exposure.